On the incorporation of chemical-specific information in risk assessment.
暂无分享,去创建一个
[1] M E Andersen,et al. Saturable metabolism and its relationship to toxicity. , 1981, Critical reviews in toxicology.
[2] Melvin E Andersen,et al. New directions in incidence-dose modeling. , 2005, Trends in biotechnology.
[3] H J Clewell,et al. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. , 1991, Toxicology and applied pharmacology.
[4] H. Clewell,et al. A Pharmacokinetic Model of the Intracellular Dosimetry of Inhaled Nickel , 2007, Journal of toxicology and environmental health. Part A.
[5] Harvey J Clewell,et al. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[6] H J Clewell,et al. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.
[7] Yu-Mei Tan,et al. Biologically motivated computational modeling of chloroform cytolethality and regenerative cellular proliferation. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.
[8] J D Graham,et al. Expert scientific judgment and cancer risk assessment: a pilot study of pharmacokinetic data. , 1988, Risk analysis : an official publication of the Society for Risk Analysis.
[9] Melvin E. Andersen,et al. Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling , 2004 .
[10] D. J. Bates,et al. Toxicokinetics of inhaled 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in F344 rats and B6C3F1 mice. , 1998, Toxicology and applied pharmacology.
[11] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[12] R. Stone. Counting the Cost of London's Killer Smog , 2002, Science.
[13] A. Renwick,et al. The use of surrogate endpoints to assess potential toxicity in humans. , 2001, Toxicology letters.
[14] W. Slob,et al. Mathematical modelling and quantitative methods. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[15] K. R. Smith,et al. Paracelsus and Goethe: founding fathers of environmental health. , 2000, Bulletin of the World Health Organization.
[16] M. Andersen,et al. Pharmacokinetic Modeling of Manganese in the Rat IV: Assessing Factors that Contribute to Brain Accumulation During Inhalation Exposure , 2008, Journal of toxicology and environmental health. Part A.
[17] H W Leung,et al. Development and utilization of physiologically based pharmacokinetic models for toxicological applications. , 1991, Journal of toxicology and environmental health.
[18] Hugh A Barton,et al. Computational Pharmacokinetics During Developmental Windows of Susceptibility , 2005, Journal of toxicology and environmental health. Part A.
[19] Harvey J Clewell,et al. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.
[20] A. Renwick. Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.
[21] M Younes,et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.
[22] Melvin E. Andersen,et al. Physiologically Based Pharmacokinetic Modeling , 2010 .
[23] M. Andersen,et al. Pharmacokinetic data needs to support risk assessments for inhaled and ingested manganese. , 1999, Neurotoxicology.
[24] G. W. Jepson,et al. Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. , 1994, Environmental health perspectives.
[25] H J Clewell,et al. Biologically motivated models for chemical risk assessment. , 1989, Health physics.
[26] H Boeing,et al. The contribution of epidemiology. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[27] R A Corley,et al. Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.
[28] Richard D. Thomas. Drinking Water and Health , 1986 .
[29] Harvey J. Clewell,et al. Improving the Development and Use of Biologically Based Dose Response Models (BBDR) in Risk Assessment , 2001 .
[30] H. Matthews,et al. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms. , 1992, Toxicology and applied pharmacology.
[31] M E Andersen,et al. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.
[32] Harvey J. Clewell. Conference on chemical risk assessment in the Department of Defense (DoD) : science, policy, and practice , 1992 .
[33] J Kleiner,et al. Assessment of intake from the diet. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[34] Melvin E. Andersen,et al. Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .
[35] A G Renwick,et al. Hazard characterisation of chemicals in food and diet. dose response, mechanisms and extrapolation issues. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[36] J W Bridges,et al. Hazard identification by methods of animal-based toxicology. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[37] Gunnar Johanson,et al. A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation , 2005, Archives of Toxicology.
[38] R. J. Lutz,et al. A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[39] Harvey J Clewell,et al. Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage , 2007, Journal of toxicology and environmental health. Part A.
[40] Hugh A Barton,et al. Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.
[41] K M Lee,et al. Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol. , 1998, Toxicology and applied pharmacology.
[42] H J Clewell,et al. Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.
[43] Renwick,et al. Human variability and noncancer risk assessment- An analysis of the default uncertainty factor , 1998, Regulatory toxicology and pharmacology : RTP.
[44] H J Clewell,et al. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. , 1989, Toxicology and applied pharmacology.
[45] Carolyn Vickers,et al. IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .
[46] A. B. Hill. The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.
[47] M. Andersen,et al. Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.
[48] Division on Earth. Risk Assessment in the Federal Government: Managing the Process , 1983 .
[49] B J Blaauboer,et al. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. , 2003, Toxicology letters.
[50] M E Andersen,et al. Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. , 1990, Toxicology and applied pharmacology.
[51] I. Hertz-Picciotto,et al. Risk characterisation of chemicals in food and diet. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[52] J. Molnar,et al. Physiologically Based Pharmacokinetic Modeling???Science and Applications , 2006 .
[53] Harvey J Clewell,et al. Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.
[54] Torsten Teorell,et al. Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .
[55] R K Jain,et al. Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.
[56] Ellen J. O'Flaherty,et al. Interspecies Conversion of Kinetically Equivalent Doses1 , 1989 .
[57] H J Clewell,et al. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. , 1996, Toxicology.
[58] Richard A. Corley,et al. Physiologically Based Pharmacokinetics and the Dermal Absorption of 2-Butoxyethanol Vapor by Humans , 1997 .
[59] H A el-Masri,et al. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. , 1995, Toxicology.
[60] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .
[61] Joseph A. Tatman,et al. Dealing with Uncertainty in Chemical Risk Analysis , 1990 .
[62] Stephen S. Olin,et al. Low-dose extrapolation of cancer risks : issues and perspectives , 1995 .
[63] M Balls,et al. Methods of in vitro toxicology. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.